Lexeo Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its gene therapy candidate LX2020 for treating PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). This designation is based on promising interim data from an ongoing Phase I/II clinical trial and highlights LX2020's potential to address the genetic cause of this serious heart disease. LX2020 also holds Orphan Drug and Fast Track statuses, which may accelerate its development and review. Lexeo plans to provide further clinical and regulatory updates later this year as it advances this one-time gene therapy for a condition with no current disease-modifying treatments.
MillerKnoll reported a strong Q1 2027 earnings per share (EPS) of $0.53, surpassing analyst expectations by over 51%, helped by tariff refunds and improved cost management. However, its revenue fell 3.4% year-over-year to $923.40 million, missing est...
THOR Industries reported Q4 earnings with an EPS of $0.78, missing analyst estimates and showing a 66.9% drop from last year. Despite this, the company beat revenue expectations with $2.31 billion, though revenue declined 8.4% year-over-year due to w...
Cracker Barrel Old Country Store is set to report its Q3 2026 earnings on September 23, with analysts predicting a significant decline. Earnings per share are expected to fall to $0.17 from $0.74 last year, and revenue is forecasted around $834.57 mi...
Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $...
HSBC and Wells Fargo have downgraded Netflix stock due to declining subscriber engagement and an 8% drop in viewership time. Despite a recent 2.19% stock gain, Netflix shares have fallen over 40% in the past year amid strong competition and weaker or...
